Fempro (Letrozole) is used to treat breast cancer in postmenopausal women, ie lacking menstruation due to age or after surgery or chemotherapy. Fempro (letrozole in the UK) produced in the form of tablets containing 2.5 mg of active substance letrozole. Letrozole belongs to a group of substances called "aromatase inhibitors". They are also called "anti-estrogens", since they reduce the production of estrogen in the body.
Estrogen contributes to the development of certain types of breast cancer, called hormone-dependent. Reduced production of this hormone may prevent tumor growth. This drug is suitable patients using anti-estrogenic drug for the first time, and those who have already had experience with other similar drugs such as Tamoxifen in the UK.